Did GeneDx Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

PRNewsWire • Oct 27, 2026

GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the third quarter of 2026 after the market closes on Monday, November 9, 2026. Management will host a conference call that day to discuss third quarter 2026 financial and operating results at 4:30 p.m. Eastern Time. Conference Call Details Investors interested in listening to the conference ca.

Business Wire • Oct 23, 2026

GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with long-read whole genome sequencing (lrWGS). Long-read sequencing analyzes longer stretches of DNA to identify complex genetic variation, including certain structural variants and repeat expansions that can go undetected by traditional short-read sequencing. With years of published.

Business Wire • Oct 20, 2026

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research at ASHG 2026 highlights five areas: Scaling genomic interpretation with AI and machine learning: A GeneDx.

Business Wire • Oct 19, 2026

GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026.

Business Wire • Oct 7, 2026

GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx introduces Easy Order at AAP 2026 to simplify genomic testing in everyday pediatric care.

Business Wire • Oct 2, 2026

GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C.

Business Wire • Sep 9, 2026

3 Promising Genomics Stocks in the Spotlight in 2026

Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.

Zacks Investment Research • Sep 8, 2026

GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree

GAITHERSBURG, Md.--(BUSINESS WIRE)--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity.

Business Wire • Sep 1, 2026

Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside

Bears have piled into a familiar batch of volatile, heavily bet-against names, and nowhere is the wager bigger than on Venture Global, Inc. (NYSE:VG). More than 80% of its float is sold short, the steepest ratio on the market's current top-10 short-interest list, per Benzinga Pro data.

Benzinga • Aug 26, 2026